Cimetidine and Weakness - a phase IV clinical study of FDA data

Summary:

Weakness is reported as a side effect among people who take Cimetidine (cimetidine), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Benadryl, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Weakness when taking Cimetidine. It is created by eHealthMe based on reports of 10,379 people who have side effects when taking Cimetidine from the FDA, and is updated regularly.

What is Cimetidine?

Cimetidine has active ingredients of cimetidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 10,531 Cimetidine users. Check the latest studies of Cimetidine.

What is Weakness?

Weakness is found to be associated with 3,639 drugs and 6,588 conditions by eHealthMe. Check the latest studies of Weakness.

On Jan, 22, 2026

10,379 people reported to have side effects when taking Cimetidine.
Among them, 521 people (5.02%) have Weakness.

Among these 521 people:

* Approximation only. Some reports may have incomplete information.

Do you take Cimetidine and have Weakness?

- Check whether Weakness is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cimetidine:

Cimetidine (10,531 reports)

Weakness treatments and more:

Weakness (586,873 reports)

How severe was Weakness and when was it recovered:

Weakness in Cimetidine

Expand to all the drugs that have ingredients of cimetidine:

Weakness and drugs with ingredients of cimetidine (903 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cimetidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weakness:

Weakness (3,639 drugs)

Browse all the conditions that are associated with Weakness:

Weakness (6,588 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on cimetidine (the active ingredients of Cimetidine) and Cimetidine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.